Aura Biosciences Inc AURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.21
- Day Range
- $6.20–6.54
- 52-Week Range
- $4.73–9.54
- Bid/Ask
- $5.99 / $6.40
- Shares Outstanding
- 103.39M
- Market Cap
- $662.71M
- Volume/Avg
- 959,155 / 508,022
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 113
- Website
- https://www.aurabiosciences.com
Valuation
|
Metric
|
AURA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AURA
|
|---|---|
Quick Ratio | 6.87 |
Current Ratio | 7.09 |
Interest Coverage | — |
Quick Ratio
AURA
Profitability
|
Metric
|
AURA
|
|---|---|
Return on Assets (Normalized) | −58.84% |
Return on Equity (Normalized) | −71.68% |
Return on Invested Capital (Normalized) | −66.76% |
Return on Assets
AURA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Gjcncxpvx | Mkwmj | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dkwtnkfj | Npfrjcr | $64B | |||
| argenx SE ADR
ARGX
| Rmhbyrx | Xqzvb | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cwhcddpgv | Wgtjgpx | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Tqnbcvfczl | Xwnnz | $24B | |||
| BioNTech SE ADR
BNTX
| Bfphkstd | Xwg | $23B | |||
| Incyte Corp
INCY
| Jpcfbzyqw | Zmwcy | $22B | |||
| Moderna Inc
MRNA
| Fnschltgb | Hqcb | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rzdjqkhs | Bnkd | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Kfpltkqy | Ksv | $13B |
United States